Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €131.03 EUR
Change Today +0.51 / 0.39%
Volume 446.0
As of 5:04 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

actelion ltd-reg (ACT) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/21/15 - €142.50
52 Week Low
10/16/14 - €79.68
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ACTELION LTD-REG (ACT)

Related News

No related news articles were found.

actelion ltd-reg (ACT) Related Businessweek News

No Related Businessweek News Found

actelion ltd-reg (ACT) Details

Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. It offers Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; and Opsumit, an orally available endothelin receptor antagonist for the treatment of PAH to delay disease progression. The company also provides Veletri, an intravenous prostacyclin for the treatment of PAH to enhance exercise capacity; and Ventavis, an inhaled synthetic analog of prostacyclin for the treatment of PAH to enhance a composite endpoint consisting of exercise tolerance, symptoms, and lack of deterioration. In addition, it offers Valchlor, a chemotherapeutic agent for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Europe, Japan, China, Russia, Mexico, and internationally. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.

2,495 Employees
Last Reported Date: 07/21/15
Founded in 1997

actelion ltd-reg (ACT) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: SFr.2.7M
Compensation as of Fiscal Year 2014.

actelion ltd-reg (ACT) Key Developments

Actelion Creates Vaxxilon Together with the Max Planck Society

Actelion Ltd announced the creation of a start-up, together with the Max Planck Society, in the field  of synthetic carbohydrate vaccines. The new company, Vaxxilon, aims to  discover, develop, and commercialize synthetic  carbohydrate  vaccines.  Vaxxilon  has  licensed  exclusive rights to  multiple  preclinical vaccine  candidates and  additional technologies from Max- Planck  Innovation  GmbH,  the  technology  transfer  office  of  the Max Planck  Society. The company is  the  principal  investor  and  majority shareholder, having made a  funding  commitment of  up to  EUR 30 million,  to be  released in  tranches over a period of three to four years.

Shire Mulls Actelion

Shire plc (LSE:SHP) is mulling Actelion Ltd. (SWX:ATLN) for about £12 billion, according to reports.

Actelion Ltd. Presents at Citi European Healthcare Conference, Jun-15-2015

Actelion Ltd. Presents at Citi European Healthcare Conference, Jun-15-2015 . Venue: Stirling Square, 5-7 Carlton Gardens, London SW1Y 5AD, United Kingdom. Speakers: Andrew C. Weiss, Head of Investor Relations & Corporate Communications and Senior Vice President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACT:GR €131.03 EUR +0.51

ACT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $85.11 USD -1.88
H Lundbeck A/S kr161.20 DKK +0.40
Hikma Pharmaceuticals PLC 2,363 GBp -22.00
Hospira Inc $89.60 USD +0.07
UCB SA €72.61 EUR +0.41
View Industry Companies

Industry Analysis


Industry Average

Valuation ACT Industry Range
Price/Earnings 34.6x
Price/Sales 7.7x
Price/Book 11.1x
Price/Cash Flow 30.3x
TEV/Sales 7.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTELION LTD-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at